Clinical trial
Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
NCT04794101 is registered in ClinicalTrials.gov with MeiraGTx Ocular UK Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
- Lead sponsor
- MeiraGTx Ocular UK Ltd
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- December 4, 2020
- Completion date
- December 7, 2029
- Enrollment
- 97 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.
x-linked retinitis pigmentosa